Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMRPCF2)

Drug Name
MGCD265 Drug Info
Synonyms
MGCD-265; 875337-44-3; MGCD265; MGCD-265 analog; MGCD 265; N-(3-fluoro-4-(2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenylcarbamothioyl)-2-phenylacetamide; UNII-93M6577H9D; CHEMBL254760; 93M6577H9D; n-(3-fluoro-4-(2-(1-methyl-1h-imidazol-4-yl)thieno(3,2-b)pyridin-7-yloxy)phenylcarbamothioyl)-2-phenylacetamide; N-[(3-Fluoro-4-{[2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yl]oxy}phenyl)carbamothioyl]-2-phenylacetamide
Indication
Disease Entry ICD 11 Status REF
Non-small-cell lung cancer 2C25.Y Phase 2 [1]
Solid tumour/cancer 2A00-2F9Z Phase 1 [2]
Cross-matching ID
PubChem CID
24901704
ChEBI ID
CHEBI:91393
CAS Number
CAS 875337-44-3
TTD Drug ID
DMRPCF2

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Approved Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Protein kinase (PK)
Drug Name Drug ID Indication ICD 11 Highest Status REF
MGCD516 DM752PU Solid tumour/cancer 2A00-2F9Z Phase 2/3 [2]
LY2801653 DM0KJDY Biliary tract cancer 2C17 Phase 2 [2]
ENMD-2076 DMJZVPB Acute myeloid leukaemia 2A60 Phase 2 [2]
RV-568 DM652CM Asthma CA23 Phase 2 [4]
TG02 DMZFIGQ Anaplastic astrocytoma 2A00.0 Phase 1/2 [5]
LX-7101 DM2LYIN Glaucoma/ocular hypertension 9C61 Phase 1/2 [6]
Cyclocreatine DM1I7UO Virus infection 1A24-1D9Z Discontinued in Phase 1 [7]
⏷ Show the Full List of 7 Drug(s)
Drug(s) Targeting Tyrosine-protein kinase UFO (AXL)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Gilteritinib DMTI0ZO Acute myeloid leukaemia 2A60 Approved [2]
BI-505 DMSZQHX Multiple myeloma 2A83 Phase 2 [8]
Bemcentinib DM0YCPL Myelodysplastic syndrome 2A37 Phase 2 [9]
BGB-324 DMDI43Y Breast cancer 2C60-2C65 Phase 2 [10]
Mecbotamab vedotin DMU5KH4 Ovarian cancer 2C73 Phase 2 [11]
ONO-7475 DMV6GX7 Acute leukaemia 2A60 Phase 1/2 [2]
ONO-7475 DMV6GX7 Acute leukaemia 2A60 Phase 1/2 [12]
TP-0903 DMHTG8P Chronic lymphocytic leukaemia 2A82.0 Phase 1/2 [2]
Enapotamab vedotin DM1PQJO Solid tumour/cancer 2A00-2F9Z Phase 1/2 [13]
RXDX-106 DM6NVTR Solid tumour/cancer 2A00-2F9Z Phase 1 [14]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Protein kinase (PK) TTU8W4S NOUNIPROTAC Inhibitor [2]
Tyrosine-protein kinase UFO (AXL) TTZPY6J UFO_HUMAN Modulator [3]

References

1 ClinicalTrials.gov (NCT02544633) Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Company report (Mirati Therapeutics: formerly MethylGene)
4 Investigational p38 inhibitors for the treatment of chronic obstructive pulmonary disease. Expert Opin Investig Drugs. 2015 Mar;24(3):383-92.
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 Design, synthesis and biological characterization of selective LIMK inhibitors. Bioorg Med Chem Lett. 2015 Sep 15;25(18):4005-10.
7 Direct determination of creatine kinase equilibrium constants with creatine or cyclocreatine substrate. Biochim Biophys Acta. 1989 Oct 19;998(3):317-20.
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9 AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells. J Thorac Oncol. 2020 Jun;15(6):973-999.
10 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1835).
11 Clinical pipeline report, company report or official report of BioAtla
12 Clinical pipeline report, company report or official report of Ono Pharmaceutical.
13 Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer. JCI Insight. 2019 Nov 1;4(21):e128199.
14 National Cancer Institute Drug Dictionary (drug name RXDX106).